The World Health Organization has recently released global guidelines on the use of widely used GLP-1 drugs for weight loss
Aguiar-Oliveira, M
Despite the substantial progress in obesity pharmacotherapy, several critical gaps persist
95% confidence interval [CI], 0.84-0.91)
The only circumstances where compounding semaglutide or tirzepatide may be permissible are: True allergy to a specific inactive ingredient in the FDA-approved version, documented with allergy testing and medical records Documented medical need for a different concentration not commercially available, with clear clinical justification Specific patient population requiring dosage form modification , such as pediatric use, with proper medical justification Healthcare providers must document medical necessity with extensive clinical evidence
Vigilant Monitoring: Distinguishing Normal Reactions from Infection After injection, monitor for signs of possible contamination, including: Fever Increasing redness or warmth at the injection site Swelling Unusual pain These symptoms could indicate infection and require immediate medical attention
